Market Price

112.79 

-0.05 0.0%

as of May 17 '21

52 Week Range:

74.31 181.07


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jan '92 Jan '93 Jan '94 Jan '95 Jan '96 Jan '97 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 7.46
7.29
4.69
4.82
4.51
4.08
-2.85
8.65
10.90
growth rate -2.3% -35.7% 2.8% -6.4% -9.5% -100.0% 100.0% 26.0%
Earnings BIT -43.85
-73.61
-92.94
-81.95
-245.24
growth rate 0.0% 0.0% 0.0% 0.0%
ROA 3.31
1.12
-11.10
1.82
-1.70
-2.74
-39.58
-38.74
-18.29
-9.76
-15.69
growth rate -66.2% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE 9.61
3.49
-42.57
7.60
-6.41
-10.21
-58.31
-11.81
-24.21
growth rate -63.7% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0%
ROIC 4.51
1.46
-14.32
2.40
-2.23
-3.59
-60.13
-13.29
-17.23
growth rate -67.6% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 1.65
2.42
1.43
1.67
1.52
1.61
7.22
12.38
9.99
8.21
28.27
growth rate 46.7% -40.9% 16.8% -9.0% 5.9% 348.5% 71.5% -19.3% -17.8% 244.3%
Quick Ratio 0.68
0.95
0.60
0.80
0.39
0.55
6.92
11.93
9.69
7.85
27.66
growth rate 39.7% -36.8% 33.3% -51.3% 41.0% 1,158.2% 72.4% -18.8% -19.0% 252.4%
Leverage 2.80
3.44
4.40
3.95
3.59
3.88
1.22
1.21
1.75
growth rate 22.9% 27.9% -10.2% -9.1% 8.1% -32.0% -0.8% 44.6%
Balance Sheet Jan '92 Jan '93 Jan '94 Jan '95 Jan '96 Jan '97 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 3.50
12.79
35.69
47.99
53.30
growth rate 265.9% 179.1% 34.5% 11.1%
Acct.Payable 3.16
5.00
10.64
16.20
7.34
growth rate 58.3% 112.9% 52.2% -54.7%
Cur.Assets 103.09
242.94
468.99
597.36
1,888.36
growth rate 135.7% 93.1% 27.4% 216.1%
Total Assets 116.57
342.94
587.40
962.54
2,271.78
growth rate 194.2% 71.3% 63.9% 136.0%
Cash 33.59
72.28
140.54
143.23
832.98
growth rate 115.2% 94.4% 1.9% 481.6%
Inventory 2.77
7.29
9.14
15.18
22.72
growth rate 163.2% 25.4% 66.2% 49.6%
Cur.Liabilities 14.28
19.63
46.94
72.73
66.81
growth rate 37.5% 139.2% 54.9% -8.2%
Liabilities 36.87
34.33
62.45
114.54
916.19
growth rate -6.9% 81.9% 83.4% 699.9%
LT Debt 16.48
0.12
806.29
growth rate -91.5% 8,131.4%
Equity -100.30
-191.37
483.15
798.39
1,298.50
growth rate 0.0% 100.0% 65.3% 62.6%
Common Shares 21.00
23.00
23.00
25.00
24.00
24.00
71.00
71.00
30.00
91.00
98.00
growth rate 9.5% 0.0% 8.7% -4.0% 0.0% 195.8% 0.0% -57.8% 203.3% 7.7%
Cash Flow Statement Jan '92 Jan '93 Jan '94 Jan '95 Jan '96 Jan '97 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 1.77
6.68
20.20
18.72
36.17
growth rate 278.3% 202.4% -7.4% 93.3%
Cash From OA -36.71
-72.24
-72.19
-47.13
-103.93
growth rate 0.0% 0.0% 0.0% 0.0%
FCF per Share -0.24
-2.80
-0.16
1.47
-0.41
0.40
-1.02
-0.64
-1.34
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -100.0% 0.0% 0.0%
Sale Purchase of Stock 293.60
367.74
growth rate 25.3%
FCF -5.00
-67.00
-4.00
36.00
-10.00
10.00
-38.00
-81.00
-92.00
-68.00
-158.00
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Jan '92 Jan '93 Jan '94 Jan '95 Jan '96 Jan '97 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 25.25
49.84
90.64
214.38
286.73
growth rate 97.4% 81.9% 136.5% 33.8%
Op.Income -43.85
-73.61
-92.94
-81.95
-245.24
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -46.13
-83.21
-84.23
-69.72
-245.90
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -46.14
-83.22
-85.06
-75.65
-253.78
growth rate 0.0% 0.0% 0.0% 0.0%
EPS 0.71
0.24
-2.46
0.35
-0.30
-0.44
-0.65
-1.26
-2.80
-0.84
-2.60
growth rate -66.2% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 3.13
18.22
47.43
143.66
194.20
growth rate 483.2% 160.3% 202.9% 35.2%
R&D 10.86
25.56
50.71
86.29
141.36
growth rate 135.4% 98.4% 70.2% 63.8%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT -34.91
-54.62
-74.25
-81.46
-107.86
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 48.02
41.02
36.26
53.30
48.04
growth rate -14.6% -11.6% 47.0% -9.9%
Acct.Payable 24.38
15.98
18.28
7.34
22.32
growth rate -34.4% 14.4% -59.9% 204.1%
Cur.Assets 607.39
1,010.30
1,087.29
1,888.36
2,033.04
growth rate 66.3% 7.6% 73.7% 7.7%
Total Assets 948.17
1,277.54
1,262.11
2,271.78
2,346.74
growth rate 34.7% -1.2% 80.0% 3.3%
Cash 152.24
164.67
142.95
832.98
869.52
growth rate 8.2% -13.2% 482.7% 4.4%
Inventory 25.15
20.35
27.73
22.72
28.88
growth rate -19.1% 36.2% -18.1% 27.1%
Cur.Liabilities 82.32
70.05
71.97
66.81
95.50
growth rate -14.9% 2.7% -7.2% 43.0%
Liabilities 117.55
112.55
113.51
916.19
1,440.30
growth rate -4.3% 0.9% 707.2% 57.2%
LT Debt 806.29
growth rate
Equity 785.11
1,114.59
1,092.20
1,298.50
847.05
growth rate 42.0% -2.0% 18.9% -34.8%
Common Shares 0.00 0.00 0.00 0.00 0.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 9.60
9.51
9.79
7.28
growth rate -1.0% 2.9% -25.6%
Cash From OA -13.28
-23.37
-8.06
-59.22
-16.29
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 1.50
361.36
3.09
4.46
growth rate 23,926.7% -99.1% 20.2%
FCF -22.88
-32.87
-17.84
-66.51
growth rate 0.0% 0.0% 0.0%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 67.51
66.34
74.57
78.32
78.67
growth rate -1.7% 12.4% 5.0% 0.5%
Op.Income -34.91
-54.62
-74.25
-81.46
-107.86
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -31.82
-49.71
-71.60
-92.78
-107.25
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -27.73
-54.64
-77.67
-93.75
-109.66
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit 47.00
43.90
53.38
49.91
growth rate -6.6% 21.6% -6.5%
R&D 37.02
36.32
36.25
31.78
55.51
growth rate -1.9% -0.2% -12.3% 74.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (23.01)

YOY Growth Grade:

E (23.30)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -88.12 -39.18
EPS / Growth -1.28 12.6%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 12.6% 31.3% 47.1%
Future PE 0.01 0.01 31.42
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.